3 results
Approved WMOCompleted
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Approved WMOPending
To detemine whether the Paul tube induces less damage to the corneal endothelium than the Baerveldt GDD.
Approved WMORecruiting
Primary Objective: Primary objective of this trial will be to determine whether iNPWT reduces the number of patients with clinically relevant* SSOs after (potentially) contaminated ventral hernia repair <30 days after surgery. *A SSO is…